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Ibrutinib works, but does using it set patients up for potential relapse due to causing increased 
genomic instability? This question is addressed in this issue of Blood by Morande et al1, who provide 
convincing evidence that resolves a key safety issue surrounding the use of this drug, giving new 
insight into its mechanism of action.  
Ibrutinib is increasingly used as the standard of care in the treatment of chronic lymphocytic 
leukemia (CLL) where recent studies of its long term use have shown both sustained efficacy and 
acceptable tolerability2,3. Importantly, approximately a third of CLL patients relapse on ibrutinib 
therapy, and disease resistance in many of these cases is attributed to mutations in either Bruton’s 
tyrosine kinase (BTK), the target of ibrutinib, or phospholipase C2 (PLC2), a principal target of BTK 
within B cells4. Worryingly, a pre-clinical study by Compagno et al5 suggested that inhibition of BTK 
increased genomic instability in normal and neoplastic B cells via a mechanism involving enhanced 
expression of activation-induced cytidine deaminase (AID).   The implication here is that ibrutinib 
treatment may pre-destine CLL patients to drug resistance by causing increased genomic instability 
and consequent mutation in BTK and PLC2. However, the findings of Compagno et  al. were derived 
using MEC-1 cells, a CLL cell line derived from the malignant cells of a patient in prolymphocytoid 
transformation6. The effect of ibrutinib in primary CLL cells may not be the same, and this is exactly 
the data Morande et al1 present. Using a combination of observations gained from primary CLL cells 
in in-vivo and in-vitro settings, these investigators find not only that ibrutinib treatment reduces 
levels of AID in cells from patients enrolled in a clinical trial, but also that it inhibits induction of AID 
expression in primary CLL cells that are being stimulated with CD40 Ligand (CD40L) and interleukin 4 
(IL4). This latter finding is important because CD40L/IL4 is thought to be a key microenvironmental 
factor contributing to malignant clone survival and proliferation in CLL.  When coupled to the former 
finding that ibrutinib limits AID expression in vivo, there is a strong suggestion that genomic 
instability caused by microenvironmental influence can be prevented by this drug. Thus, the worry 
that ibrutinib may sow the seeds of its own demise seems to be unfounded. 
The role of microenvironment in CLL cannot be understated. By playing a role in survival and 
proliferation of the malignant cells in this disease, microenvironmental influences contribute in a 
major way to the expansion of clones that are resistant to therapy. Within this context ibrutinib 
targets BTK to simultaneously cause redistribution lymphocytosis by impeding the ability of CLL cells 
to reside within proliferation centres, and blocking the ability of these cells to respond to 
chemokines that stimulate entry/re-entry to this environment7. This effect on decreasing tumour 
burden is augmented by the reduced proliferation and enhanced death of CLL cells that is observed 
in patients being treated with ibrutinib8. Thus, our current understanding of ibrutinib’s therapeutic 
effect is that it is mediated by removing CLL cells from proliferation centres and reducing their 
overall survival. Morande et al1 add to this understanding by measuring AID expression in CLL cells 
that are Ki-67 positive, and showing that this population of cells is severely reduced after patients 
begin taking ibrutinib. This means that ibrutinib treatment blocks the means of creating mutation 
within CLL cells, as well as the means through which clones bearing mutation can be expanded. So 
why do patients on ibrutinib develop resistance, particularly that associated with mutation of BTK 
and PLC2? The answer to this is not clear but could be related to the amount of treatment received 
by a given patient prior to ibrutinib therapy. Such patients are particularly prone to developing 
ibrutinib resistance4, likely from clones already containing mutant BTK and PLC2 that are reported 
present at low frequency9 rather than through de-novo mutagenesis.  
So how does ibrutinib affect CLL cells in patients? This compound has a high degree of specificity for 
BTK, and the main downstream targets of this tyrosine kinase in B cells are PLC2 and Wiskott-
Aldrich syndrome protein (WASp), but this might not be all it does. To more fully understand how 
ibrutinib therapy impacts CLL cells, Morande et al isolated malignant cells bearing a phenotype 
associated with having a high proliferative index from CLL patients enrolled on a clinical trial before 
and during receipt the drug. They then performed a phospho-protein analysis on these cells and 
identified that ibrutinib treatment leads to dephosphorylation of JAK1 at Tyr1022, an event that 
deactivates the function of this kinase. Active JAK1 in cells stimulates the phosphatidylinositol 3-
kinase (PI3K) pathway, and consistent with its deactivation in ibrutinib-treated CLL cells the authors 
observe changes in the phosphorylation of key proteins connected with this pathway that function in 
controlling proliferation and apoptosis. This could possibly account for the reduction of cells 
expressing Ki-67 and the increase in CLL cell death that is observed in these patients. The 
explanation for reduced AID expression is that JAK1 targets STAT6 for phosphorylation, which then 
translocates to the cell nucleus and is responsible for induction of AID expression. Indeed, Morande 
et al model this in vitro and show that ibrutinib treatment of CD40L/IL4-stimulated CLL cells reduces 
STAT6 phosphorylation and AID expression. Thus, a potentially new role for BTK can be applied that 
is different to its typical role in the BCR signalling pathway (Figure A). In this new role BTK is key to 
modulating JAK1 activation within CLL cells stationed within the microenvironment and exposed to 
CD40L/IL4 (Figure B). It is known that BTK becomes activated in CD40-stimulated B cells10, and within 
this context there may be new substrates, such as protein tyrosine phosphatases, that are able to 
dephosphorylate JAK1 and STAT6 and downregulate IL4 signalling. To find this out will require 
further experiments comparing the effect of ibrutinib on CLL cells incubated with IL4 alone and with 
CD40L/IL4.  
This manuscript therefore sets the stage for further work into the mechanism of action of ibrutinib 
and similar compounds. These compounds can no longer be referred to as just BCR signalling 
pathway inhibitors, it seems they also affect a key pathway responsible for the development and 
expansion of resistant clones. Thus, ibrutinib is safer than we thought and may be most useful as a 
front line therapy.  
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 Figure. Central role of BTK in the regulation of BCR- and CD40L/IL4-induced signalling. A.) BTK is 
centrally involved in the BCR signalling pathway, sitting distal to Syk and PI3K, to phosphorylate and 
activate PLC2 and WASp leading to further signal pathway activation and actin cytoskeleton 
rearrangements, respectively. B.) The mechanism of how BTK is activated by CD40 ligation is 
unknown, but could involve PI3K isoforms other than PI3K (involved in BCR signalling). Active BTK 
then potentially interacts with a protein tyrosine phosphatase, which subsequently 
dephosphorylates JAK1 and STAT6 to deactivate their function in promoting cell proliferation 
(through the PI3K pathway) and induction of AID expression. Ag, antigen; BLNK, B-cell linker protein; 
ERK, extracellular signal-regulated kinase; IL-4R, IL-4 receptor; NFAT, nuclear factor of activated T 
cells; P, phosphorylated tyrosine; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, 
phosphatidylinositol (3,4,5)-trisphosphate; TRAF, tumor necrosis factor receptor–associated factor. 
